Banzel approved for Lennox-Gastaut syndrome (LGS)
The FDA has approved Banzel (rufinamide, from Eisai) tablets as an adjunct treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥4 years of age. In a double-blind, placebo-controlled study, Banzel-treated patients had a 42.5% median reduction in the frequency of drop attacks, seizures that cause falling to the ground and loss of consciousness, as compared to a 1.4% median increase in placebo-treated patients.
Banzel is expected to be available in January 2009 in 200mg and 400mg dosage strengths.
For more information call (888) 274-2378 or visit www.eisai.com.